CAR-T therapies have been a game changer for certain blood cancers, but the approach still needs some ironing out. Some patients may relapse, for instance, while others may not have the time or the T cells for a bespoke treatment.

Researchers at Battelle and Ohio State University have developed a brain-computer interface that not only allows a paralyzed person to move their hand but also to regain a sense of touch.

Veracyte has been granted an exclusive license to a genomic blood test developed at Yale University capable of predicting the progression of idiopathic pulmonary fibrosis, or IPF.

Nearly a decade ago, researchers at UT Southwestern Medical Center discovered that when mouse hearts were damaged in the first seven days of life, they would regenerate. They reasoned that if they could find a way to recreate that regenerative ability later in life, it might provide a new way to treat heart damage.

Sanofi has posted the data that led it to start four phase 3 trials of its Principia Biopharma-partnered multiple sclerosis drug SAR442168. The phase 2 linked the BTK inhibitor to relative reductions in new lesions of 85% or more, but criticism of the study design means doubts remain as the program enters the pivotal stage.

Patients with chronic kidney disease (CKD) may take medicines for blood pressure and other related conditions, undergo regular dialysis treatments or even require a transplant. But what their care often neglects is pruritis—the stubborn, systemic itch that plagues as many as 40% of dialysis patients. With positive phase 3 data, Cara Therapeutics is one step closer to changing that.

Widely prescribed broad-spectrum antibiotics such as amoxicillin can kill off many types of bacteria indiscriminately, including harmless strains. But that can lead to resistance that bugs can pass on to other pathogenic bacteria. Compounds that target specific bacterial infections instead could help combat the problem of antibiotics resistance.

The loss of light-sensing cells in the retina called photoreceptors is associated with several eye diseases, including age-related macular degeneration (AMD), a leading cause of blindness in older people. Many attempts to restore light-sensing cells have involved coaxing stem cells to become photoreceptors.

At a time that hepatitis B programs seem to be dropping like flies, Vir Biotechnology has some good news. Its gene-silencing drug cut levels of the hepatitis B surface antigen in a small phase 2 study in patients already taking antiretroviral drugs.

Boehringer Ingelheim has tapped artificial intelligence maven Insilico Medicine to help identify new drug targets through its internal Research Beyond Borders initiative, which is tasked with forming new collaborations outside of the company’s traditional therapeutic areas and geographies.